Usted buscó: panitumumab (Inglés - Lituano)

panitumumab
panitumumabas

panitumumab + folfiri
panitumumabas + folfiri

each vial contains 200 mg panitumumab.
viename buteliuke yra 200 mg panitumumabo.

each vial contains 100 mg of panitumumab.
viename buteliuke yra 100 mg panitumumabo.

it contains the active substance panitumumab.
jo sudtyje yra veikliosios medziagos panitumumabo.

each ml of concentrate contains 20 mg panitumumab.
viename mililitre koncentrato yra 20 mg panitumumabo.

vectibix 20 mg/ml sterile concentrate panitumumab
vectibix 20 mg/ml sterilus koncentratas panitumumab i.v.

the active substance is panitumumab 20 mg/ml.
veiklioji medziaga yra panitumumabas.viename mililitre koncentrato jo yra 20 mg.

vectibix 20 mg/ ml sterile concentrate panitumumab iv
vectibix 20 mg/ ml sterilus koncentratas panitumumab i. v.

there was an increase in mortality in the panitumumab arm.
panitumumabu gydytų pacientų grupėje mirtingumas buvo didesnis.

vectibix 20 mg/ ml concentrate for solution for infusion panitumumab
vectibix 20 mg/ ml koncentratas infuziniam tirpalui panitumumabas (panitumumab)

colourless solution that may contain visible amorphous panitumumab particles.
bespalvis tirpalas, kuriame gali bti matom amorfini panitumumabo daleli.

panitumumab may impact the ability of a woman to become pregnant.
panitumumabas gali veikti moters gebėjimą pastoti.

panitumumab does not seem to work in tumour cells that contain mutated kras.
panitumumabas neveiksmingas naviko lstelse, kuriose yra mutavs kras.

lactation it is unknown whether panitumumab is excreted in human breast milk.
zindymo laikotarpisnezinoma, ar panitumumabo patenka motinos pien.

panitumumab does not seem to work in tumour cells that contain mutated ras genes.
panašu, kad panitumumabas neveikia naviko, kuriame yra mutavę ras genai, ląstelių.

studies to evaluate the mutagenic and carcinogenic potential of panitumumab have not been performed.
tyrimų, kuriais galima įvertinti panitumumabo gebėjimą sukelti mutageninį ir kancerogeninį poveikį, neatlikta.

this may be due to patients receiving panitumumab after progression among those randomized to bsc.
taip galjo bti dl to, kad vien tik tpg gav pacientai, kuri liga progresavo, pradjo vartoti panitumumab.

no pre- and post-natal development animal studies have been conducted with panitumumab.
panitumumabo poveikio prenataliniam ir postnataliniam gyvūnų vystymuisi tyrimų neatlikta.

skin reactions were the most frequently occurring adverse reactions in patients receiving panitumumab in combination with chemotherapy.
odos reakcijos buvo dažniausios nepageidaujamos reakcijos pasireiškusios pacientams, vartojantiems panitumumabą kartu su chemoterapija.